2 completed, 2 recruiting, 1 terminated. 2 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Waldenstrom's Disease: new trials by email Literature Review of Waldenstrom's Disease trials Research Report on Waldenstrom's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease Waldenstrom's Disease, Prognostic Index | Recruiting | French Innovative Leukemia Organisation | 500 | 2023-08-11 | 2025-11-26 | |
| Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia bone marrow sample, blood sample - Waldenstrom's Disease, Waldenstrom Macroglobulinemia | Not applicable | Recruiting | Centre Hospitalier Universitaire, Amiens | 90 | 2022-05-16 | 2025-09-09 |
| Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia Ibrutinib, Daratumumab - Waldenstrom Macroglobulinemia, Waldenstrom's Disease | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2020-07-30 | 2023-10-23 |
| Detection of Recurrent Mutations in Waldenström's Disease Determination of mutation - Waldenstrom's Disease | Not applicable | Completed | Centre Henri Becquerel | 45 | 2019-01-14 | 2026-01-02 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies CDX-1140, CDX-301, pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 | Completed | Celldex Therapeutics | 132 | 2017-12-01 | 2024-03-28 |
Waldenstrom Macroglobulinemia (2) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Hyper-IgM Immunodeficiency Syndrome (1) · Hypergammaglobulinemia (1) · Kidney Neoplasms (1) · Laryngeal Neoplasms (1)
Blood Protein Disorders (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Vascular Diseases (2)
Blood Specimen Collection (1) · Drug Therapy (1) · daratumumab (1) · ibrutinib (1) · pembrolizumab (1)
Celldex Therapeutics (1) · Centre Henri Becquerel (1) · Centre Hospitalier Universitaire, Amiens (1) · French Innovative Leukemia Organisation (1) · Weill Medical College of Cornell University (1)
France (3) · United States (2)
John N. Allan, M.D. (1) · Pascaline Etancelin (1)